scholarly journals Metabolomics Monitoring of Treatment Response to Brain Tumor Immunotherapy

2021 ◽  
Vol 11 ◽  
Author(s):  
Farhad Dastmalchi ◽  
Loic P. Deleyrolle ◽  
Aida Karachi ◽  
Duane A. Mitchell ◽  
Maryam Rahman

Immunotherapy has revolutionized care for many solid tissue malignancies, and is being investigated for efficacy in the treatment of malignant brain tumors. Identifying a non-invasive monitoring technique such as metabolomics monitoring to predict patient response to immunotherapy has the potential to simplify treatment decision-making and to ensure therapy is tailored based on early patient response. Metabolomic analysis of peripheral immune response is feasible due to large metabolic shifts that immune cells undergo when activated. The utility of this approach is under investigation. In this review, we discuss the metabolic changes induced during activation of an immune response, and the role of metabolic profiling to monitor immune responses in the context of immunotherapy for malignant brain tumors. This review provides original insights into how metabolomics monitoring could have an important impact in the field of tumor immunotherapy if achievable.

2007 ◽  
Vol 18 (2) ◽  
pp. 225-247 ◽  
Author(s):  
Andrew Clifford

This article examines the part that healthcare interpreters play in cross-cultural medical ethics, and it argues that there are instances when the interpreter needs to assume an interventionist role. However, the interpreter cannot take on this role without developing expertise in the tendencies that distinguish general communication from culture to culture, in the ethical principles that govern medical communication in different communities, and in the development of professional relationships in healthcare. The article describes each of these three variables with reference to a case scenario, and it outlines a number of interventionist strategies that could be potentially open to the interpreter. It concludes with a note about the importance of the three variables for community interpreter training. Keywords: community interpreting, informed consent, role of the interpreter, healthcare.


2010 ◽  
Vol 19 (13-14) ◽  
pp. 2023-2031 ◽  
Author(s):  
Gill Hubbard ◽  
Nicola Illingworth ◽  
Neneh Rowa-Dewar ◽  
Liz Forbat ◽  
Nora Kearney

Author(s):  
Amiram Gafni ◽  
Cathy Charles

Shared decision-making (SDM) between physicians and patients is often advocated as the ‘best’ approach to treatment decision-making in the clinical encounter. In this chapter we describe: (i) the key characteristics of a SDM approach; (ii) the clinical contexts for SDM; (iii) the definition and use of decision aids (DA), as well as their relationship to SDM; and (iv) the vexing problem of defining the meaning and role of values/preferences in treatment decision-making. Areas for further research and conceptual development are also suggested to help resolve outstanding issues in the above areas. Despite the widespread interest in promoting SDM, there does not seem to be as yet a universally accepted consensus on the meaning of this concept.


Biomedicines ◽  
2019 ◽  
Vol 7 (4) ◽  
pp. 86 ◽  
Author(s):  
Maifata ◽  
Hod ◽  
Zakaria ◽  
Abd Ghani

The detection of phospholipase A2 receptor (PLA2R) and thrombospondin domain containing 7A THSD7A among primary membranous glomerulonephritis (MGN) patients transformed the diagnosis, treatment monitoring, and prognosis. Anti-PLA2R can be detected in 70–90% of primary MGN patients while anti-THSD7A in 2–3% of anti-PLA2R negative primary MGN patients depending on the technique used. Serum and urine samples are less invasive and non-invasive, respectively, and thus can detect the presence of anti-PLA2R and anti-THSD7A with higher sensitivity and specificity, which is significant in patient monitoring and prognosis. It is better than exposing patients to a frequent biopsy, which is an invasive procedure. Different techniques of detection of PLA2R and THSD7A in patients’ urine and sera were reviewed to provide newer and alternative techniques. We proposed the use of biomarkers (PLA2R and THSD7A) in the diagnosis, treatment decision, and follow-up of patients with primary MGN. In addition, other prognostic renal biomarkers like retinol binding protein (RBP) and beta-2 microglobulin were reviewed to detect the progression of renal damage for early intervention.


2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 5523-5523 ◽  
Author(s):  
Lorraine Margaret Elit ◽  
Anthony W. Fyles ◽  
Chu-Shu Gu ◽  
Gregory Russell Pond ◽  
David D'Souza ◽  
...  

2011 ◽  
Vol 11 (1) ◽  
Author(s):  
Shedra Amy Snipes ◽  
Sherrill L Sellers ◽  
Adebola Odunlami Tafawa ◽  
Lisa A Cooper ◽  
Julie C Fields ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document